• 1
    Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol. 2004; 15: 1467-1475.
  • 2
    Hu WH, Chen M, Sun Y, et al. Multivariate prognostic analysis of stage I(E) primary non-Hodgkin's lymphomas of the nasal cavity. Am J Clin Oncol. 2001; 24: 286-289.
  • 3
    Aviles A, Díaz NR, Neri N, Cleto S, Talavera A. Angiocentric nasal T/natural killer cell lymphoma: a single centre study of prognostic factors in 108 patients. Clin Lab Haematol. 2000; 22: 215-220.
  • 4
    Oshimi K, Kawa K, Nakamura S, et al; NK-cell Tumor Study Group. NK-cell neoplasms in Japan. Hematology. 2005; 10: 237-245.
  • 5
    Au WY, Weisenburger DD, Intragumtornchai T, et al; International Peripheral T-Cell Lymphoma Project. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood. 2009; 113: 3931-3937.
  • 6
    Au WY, Ma SY, Chim CS, et al. Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years. Ann Oncol. 2005; 16: 206-214.
  • 7
    Ng SB, Lai KW, Murugaya S, et al. Nasal-type extranodal natural killer/T-cell lymphomas: a clinicopathologic and genotypic study of 42 cases in Singapore. Mod Pathol. 2004; 17: 1097-1107.
  • 8
    Altemani A, Barbosa AC, Kulka M, et al. Characteristics of nasal T/NK-cell lymphoma among Brazilians. Neoplasma. 2002; 49: 55-60.
  • 9
    You JY, Chi KH, Yang MH, et al. Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan. Ann Oncol. 2004; 15: 618-625.
  • 10
    Koom WS, Chung EJ, Yang WI, et al. Angiocentric T-cell and NK/T-cell lymphomas: radiotherapeutic viewpoints. Int J Radiat Oncol Biol Phys. 2004; 9: 1127-1137.
  • 11
    Cheung MM, Chan JK, Lau WH, et al. Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol. 1998; 16: 70-77.
  • 12
    Li YX, Bo Y, Jing J, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol. 2006; 24: 181-189.
  • 13
    Ribrag V, Ell Hajj M, Janot F, et al. Early locoregional high-dose radiotherapy is associated with long-term disease control in localized primary angiocentric lymphoma of the nose and nasopharynx. Leukemia. 2001; 15: 1123-1126.
  • 14
    Yamaguchi M, Ogawa S, Nomoto Y, et al. Treatment outcome of nasal NK-cell lymphoma: a report of 12 consecutively-diagnosed cases and a review of the literature. J Clin Exp Hematol. 2001; 41: 93-99.
  • 15
    Kim WS, Song SY, Ahn YC, et al. CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma? Ann Oncol. 2001; 12: 349-352.
  • 16
    Au WY. Current management of nasal NK/T-cell lymphoma. Oncology (Williston Park). 2010; 24: 352-358.
  • 17
    National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology for Non-Hodgkin's Lymphomas. Version 3. 2011. Available at: Accessed July 18, 2011.
  • 18
    Jaccard A, Petit B, Girault S, et al. L-Asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature. Ann Oncol. 2009; 20: 110-116.
  • 19
    Yong W, Zheng W, Zhu J, et al. L-Asparaginase in the treatment of refractory and relapsed extranodal NK/T-cell lymphoma, nasal type. Ann Hematol. 2009; 88: 647-652.
  • 20
    Yamaguchi M, Suzuki R, Kwong YL, et al. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci. 2008; 99: 1016-1020.
  • 21
    Obama K, Tara M, Niina K. L-Asparaginase-based induction therapy for advanced extranodal NK/T-cell lymphoma. Int J Hematol. 2003; 78: 248-250.
  • 22
    Chim CS, Ma SY, Au WY, et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the international prognostic index. Blood. 2004; 103: 216-221.
  • 23
    Li CC, Tien HF, Tang JL, et al. Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma. Cancer. 2004; 100: 366-375.
  • 24
    Huang MJ, Y Jiang, Liu WP, et al. Early or up-front radiotherapy improved survival of localized extranodal NK/T-cell lymphoma, nasal-type in the upper aerodigestive tract. Int J Radiat Oncol Biol Phys. 2008; 70: 166-174.
  • 25
    Chan JKC, Quintanilla-Martinez L, Ferry JA, et al. Extranodal NK/T-cell lymphoma, nasal type. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classfication of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon, France: IARC Press; 2008: 285-288.
  • 26
    Lee J, Suh C, Park YH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol. 2006; 24: 612-618.
  • 27
    Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999; 17: 1244.
  • 28
    Wu X, Li P, Zhao J, et al. A clinical study of 115 patients with extranodal natural killer/T-cell lymphoma, nasal type. Clin Oncol (R Coll Radiol). 2008; 20: 619-625.
  • 29
    Cheung MM, Chan JK, Lau WH, Ngan RK, Foo WW. Early stage nasal T/NK-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys. 2002; 54: 182-190.
  • 30
    Kim BS, Kim TY, Kim CW, et al. Therapeutic outcome of extranodal T/NK-cell lymphoma initially treated with chemotherapy–result of chemotherapy in T/NK-cell lymphoma. Acta Oncol. 2003; 42: 779-783.
  • 31
    Kim K, Chie EK, Kim CW, Kim IH, Park CI. Treatment outcome of angiocentric T-cell and NK/T-cell lymphoma, nasal type: radiotherapy versus chemoradiotherapy. Jpn J Clin Oncol. 2005; 35: 1-5.
  • 32
    Bossard C, Belhadj K, Reyes F, et al. Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood. 2007; 109: 2183-2189.
  • 33
    Wang B, Li XQ, Ma X, Hong X, Lu H, Guo Y. Immunohistochemical expression and clinical significance of P-glycoprotein in previously untreated extranodal NK/T-cell lymphoma, nasal type. Am J Hematol. 2008; 83: 795-799.
  • 34
    Yamaguchi M, Tobinai K, Oguchi M, et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma. Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol. 2009; 27: 5594-5600.
  • 35
    Kim SJ, Kim K, Kim BS, et al. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-cell lymphoma: Consortium for Improving Survival of Lymphoma study. J Clin Oncol. 2009; 27: 6027-6032.
  • 36
    Isobe K, Uno T, Tamaru J, et al. Extranodal natural killer/T-cell lymphoma, nasal type: the significance of radiotherapeutic parameters. Cancer. 2006; 106: 609-615.
  • 37
    Tham IW, Lee KM, Yap SP, Loong SL. Outcome of patients with nasal natural killer (NK)/T-cell lymphoma treated with radiotherapy, with or without chemotherapy. Head Neck. 2006; 28: 126-134.